Login to Your Account



Actelion Rises on Safety Data Despite Macitentan Miss in IPF

By Cormac Sheridan


Wednesday, August 31, 2011
A Phase II trial miss is usually nothing to shout about, but Actelion Pharmaceuticals Ltd. put an optimistic gloss on macitentan's failure to demonstrate efficacy in idiopathic pulmonary fibrosis (IPF), emphasizing its favorable safety profile, which could augur well for an ongoing Phase III trial in pulmonary arterial hypertension (PAH).

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription